Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647636 | 1.00 | DPP4 (0.62) | DPP4DPP9EPHX2TEAD1DPP8 | |
| SCHEMBL646636 | 0.91 | DPP4 (0.61) | DPP4DPP9EPHX2 | |
| SCHEMBL650946 | 0.90 | DPP4 (0.58) | DPP4DPP9EPHX2DPP8 | |
| SCHEMBL646035 | 0.90 | DPP4 (0.58) | DPP4DPP9EPHX2DPP8 | |
| SCHEMBL6511797 | 0.90 | DPP4 (0.61) | DPP4DPP9EPHX2TEAD1DPP8 | |
| SCHEMBL647238 | 0.90 | DPP4 (0.61) | DPP4DPP9EPHX2TEAD1DPP8 | |
| SCHEMBL6511792 | 0.90 | DPP4 (0.61) | DPP4DPP9EPHX2TEAD1DPP8 | |
| SCHEMBL648643 | 0.88 | DPP4 (0.68) | DPP4DPP9EPHX2DPP8 | |
| SCHEMBL646737 | 0.88 | DPP4 (0.64) | DPP4DPP9EPHX2DPP8 | |
| SCHEMBL4703708 | 0.88 | DPP4 (0.68) | DPP4DPP9EPHX2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637546-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV) | ABBVIE INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC. | 2013-03-07 | — | — | US | disclosed |
| US-8119664-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| EP-1560811-B9 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | MADAR DAVID J | 2007-11-15 | — | — | US | disclosed |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | disclosed |
| US-7262207-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1560811-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885EPHX2 2757/4885 |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885EPHX2 2757/4885 |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885EPHX2 2757/4885 |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885EPHX2 2757/4885 |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885EPHX2 2739/4885 |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885EPHX2 2739/4885 |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885EPHX2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.